NZ Lymphoma / Leukaemia Research Review Issue 53

In this issue:
  Leukaemia selection
  -  Oral azacitidine maintenance for AML in first remission
  -  Fixed-duration, MRD-guided approach in CLL
  -  Novel DHODH inhibitor for treating myeloid malignancies
  -  Impact of cytogenetic risk on HSCT outcomes in relapsed/ refractory AML
  -  Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1-mutated AML
  -  Clinical characteristics and outcomes of AML with both FLT3-ITD and IDH mutations
  Lymphoma selection
  -  Long-term results of PETguided RT in advanced-stage DLBCL treated with R-CHOP
  -  Pembrolizumab then AVD in untreated early unfavourable and advanced classical HL
  -  Lenalidomide maintenance after autologous HSCT in mantle cell lymphoma
  -  PET-guided omission of RT in early-stage unfavourable HL

Please login below to download this issue (PDF)